Covid19 Clinical Trial
— CHARTER-IrlOfficial title:
Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland
The investigators present a randomised open label phase Ib/IIa trial of nebulised unfractionated heparin to evaluate the effect of nebulised unfractionated heparin on the procoagulant response in ICU patients with SARS-CoV-2 requiring advanced respiratory support. As this is one of the first studies of nebulised heparin in COVID 19 lung disease the investigators will assess safety as a co-primary outcome.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | January 2022 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: To be eligible, a patient must satisfy all these inclusion criteria: 1. Confirmed or suspected COVID-19. Note, if 'suspected', results must be pending or testing intended 2. Ability to obtain informed consent/assent to participate in study 3. Age 18 years or older 4. Requiring high flow nasal oxygen or positive pressure ventilator support or invasive mechanical ventilation for a time period of no greater than 48 hours 5. D-dimers > 200 ng/ml 6. PaO2 to FIO2 ratio less than or equal to 300 7. Acute opacities on chest imaging affecting at least one lung quadrant. Note 'Acute opacities' do not include effusions, lobar/lung collapse or nodules 8. Currently in a higher level of care area designated for inpatient care of patients where therapies including non-positive pressure ventilatory support can be provided. Exclusion criteria To be eligible, a patient must have none of these exclusion criteria: 1. Enrolled in another clinical trial that is unapproved for co-enrolment 2. Heparin allergy or heparin-induced thrombocytopaenia 3. APTT > 100 seconds 4. Platelet count < 50 x 109 per L 5. Pulmonary bleeding, which is frank bleeding in the trachea, bronchi or lungs with repeated haemoptysis or requiring repeated suctioning 6. Uncontrolled bleeding 7. Pregnant or suspected pregnancy (Urine or serum HCG will be recorded) 8. Receiving or about to commence ECMO or HFOV 9. Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome 10. Usually receives home oxygen 11. Dependent on others for personal care due to physical or cognitive decline (pre-morbid status) 12. Death is imminent or inevitable within 24 hours 13. The clinical team would not be able to set up the study nebuliser and ventilator circuit as required including with active humidification 14. Clinician objection. 15. The use or anticipated use of nebulised tobramycin during this clinical episode 16. Any other specific contraindication to anticoagulation including prophylactic anticoagulation not otherwise listed here 17. Relapse in clinical condition in patient that had fully weaned from advanced respiratory support 18. Any systemic anticoagulation other than prophylactic anticoagulation |
Country | Name | City | State |
---|---|---|---|
Ireland | University Hospital Galway | Galway |
Lead Sponsor | Collaborator |
---|---|
University College Hospital Galway |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | D-dimer profile | Effect of nebulised heparin on d-dimer profile, assessed via d-dimer AUC and via a mixed effects model, with data collected on days 1, 3, 5 and 10. | Up to day 10. | |
Primary | Frequenccy of Severe Adverse Outcomes | Safety of nebulised heparin delivered by aerogen solo nebuliser in patients with COVID-19 induced severe respiratory failure, as measured by the incidence of severe adverse events. | Up to day 60 | |
Secondary | Oxygenation Index | Determine the impact of nebulised heparin on oxygenation index | Up to day 10 | |
Secondary | Indices of Inflammation | Effect of nebulised heparin on indices of inflammation (Interleukin (IL)-1ß, IL-6, IL-8, IL-10 and soluble TNF receptor 1 (sTNFR1), C-reactive protein, procalcitonin, Ferritin,) will be assessed (AUC on days 1, 3, 5 and 10) | Up to day 10 | |
Secondary | Ratios of Indices of Inflammation | Effect of nebulised heparin on the ratios of IL-1ß/IL-10 and IL-6/IL-10 will also be assessed. | Up to day 10 | |
Secondary | Indices of Coagulation | Effect of nebulised heparin on other indices of coagulation (Fibrinogen; lactate dehydrogenase) will be assessed (AUC on days 1, 3, 5 and 10). | Up to day 10 | |
Secondary | Quasi-Static Lung Compliance | Determine the effect of nebulised heparin on Quasi-Static Lung Compliance (i.e. tidal volume/(Plateau pressure-PEEP) measured on days 1,3,5,10. | Up to day 10 | |
Secondary | Time to separation from advanced respiratory support | Time to separation from advanced respiratory support, where non survivors are treated as though not separated from advanced respiratory support. | Up to day 28 | |
Secondary | Number treated with neuromuscular blockers | Number treated with neuromuscular blockers instituted after enrolment | Up to day 10 | |
Secondary | Number treated with Prone positioning | Number treated with prone positioning instituted after enrolment | Up to day 10 | |
Secondary | Number treated with extra-corporeal membrane oxygenation | Number treated with extra-corporeal membrane oxygenation instituted after enrolment | Up to day 10 | |
Secondary | Number requiring Tracheostomy | Number tracheotomised | Up to day 28 | |
Secondary | Time to separation from invasive ventilation among survivors | Time to separation from invasive ventilation among survivors | Up to day 28 | |
Secondary | Discharge to ward | Time to separation from the ICU to day 28, where non-survivors to day 28 are treated as though not separated from invasive care | Up to day 28 | |
Secondary | Discharge to ward in survivors | Time to discharge from the ICU to day 28, among survivors | Up to day 28 | |
Secondary | Patient Survival | Survival to day 28; Survival to day 60; and Survival to hospital discharge, censored at day 60 | Up to day 60 | |
Secondary | Number of patients residing at home or in a community setting at day 60 | Number residing at home or in a community setting at day 60 | Up to day 60 | |
Secondary | Number of surviving patients residing at home or in a community | Number residing at home or in a community setting at day 60, among survivors | Up to day 60 | |
Secondary | Ventilatory ratio | Effect of nebulised heparin on ventilatory ratio measured every 6 hours | Up to day 10 | |
Secondary | Number treated with awake prone positioning | Number of patients treated with awake prone positioning | Up to day 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |